Susan Scott1, Matthew Roberts1, Eric Chung2. 1. Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. 2. Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia; AndroUrology Centre, Brisbane, QLD, Australia; Department of Urology, Macquarie University Hospital, Sydney, NSW, Australia. Electronic address: ericchg@hotmail.com.
Abstract
BACKGROUND: Platelet-rich plasma (PRP) injections have recently been marketed as a form of autologous cell therapy under the banner of regenerative medicine despite limited scientific evidence on its use for treating erectile dysfunction (ED). AIM: To evaluate the evidence on PRP treatment for ED and determine the current trends in provision of this treatment. METHODS: A critical review of the literature on PRP using the PubMed and Embase databases. OUTCOMES: This narrative review focuses on the clinical use of, regulation of, and evidence for PRP in the treatment of ED. RESULTS: There is a limited number of published peer-reviewed articles demonstrating clinical outcomes pertaining to the use of PRP for ED in human. The technique of PRP application for ED is currently patented, with a global total of 683 registered clinics. The majority of PRP clinics do not provide cost estimates on their websites. CONCLUSION: Despite a global presence of PRP clinics and ongoing active marketing and public interest in regenerative medicine, no scientific evidence has been published to establish an evidence-based risk-benefit profile for PRP use for ED in humans. Given the limited data on clinical efficacy and potential harmful side effects, there is a need for a proper clinical trial to examine the role of PRP before it is accepted as standard of care in treatment for ED. Scott S, Roberts M, Chung E. Platelet-Rich Plasma and Treatment of Erectile Dysfunction: Critical Review of Literature and Global Trends in Platelet-Rich Plasma Clinics. Sex Med Rev 2019;7:306-312.
BACKGROUND: Platelet-rich plasma (PRP) injections have recently been marketed as a form of autologous cell therapy under the banner of regenerative medicine despite limited scientific evidence on its use for treating erectile dysfunction (ED). AIM: To evaluate the evidence on PRP treatment for ED and determine the current trends in provision of this treatment. METHODS: A critical review of the literature on PRP using the PubMed and Embase databases. OUTCOMES: This narrative review focuses on the clinical use of, regulation of, and evidence for PRP in the treatment of ED. RESULTS: There is a limited number of published peer-reviewed articles demonstrating clinical outcomes pertaining to the use of PRP for ED in human. The technique of PRP application for ED is currently patented, with a global total of 683 registered clinics. The majority of PRP clinics do not provide cost estimates on their websites. CONCLUSION: Despite a global presence of PRP clinics and ongoing active marketing and public interest in regenerative medicine, no scientific evidence has been published to establish an evidence-based risk-benefit profile for PRP use for ED in humans. Given the limited data on clinical efficacy and potential harmful side effects, there is a need for a proper clinical trial to examine the role of PRP before it is accepted as standard of care in treatment for ED. Scott S, Roberts M, Chung E. Platelet-Rich Plasma and Treatment of Erectile Dysfunction: Critical Review of Literature and Global Trends in Platelet-Rich Plasma Clinics. Sex Med Rev 2019;7:306-312.
Authors: Mohammed Monirul Islam; Nimbagal Raghavendra Naveen; Posina Anitha; Prakash S Goudanavar; G S N Koteswara Rao; Santosh Fattepur; Muhammad Muhitur Rahman; Predeepkumar Narayanappa Shiroorkar; Mohammed Habeebuddin; Girish Meravanige; Mallikarjun Telsang; Sreeharsha Nagaraja; Syed Mohammed Basheeruddin Asdaq; M D Khalid Anwer Journal: J Clin Med Date: 2022-05-31 Impact factor: 4.964
Authors: Premal Patel; Jonathan Katz; Soum D Lokeshwar; Manuel Molina; Isildinha M Reis; Raul Clavijo; Ranjith Ramasamy Journal: Sex Med Date: 2020-03-14 Impact factor: 2.491